Be a Smart Investor
Thursday, June 28, 2018
Summit Therapeutics (SMMT) Tanked After Phase 2 Study Failed
Summit Therapeutics (SMMT) announced Wednesday morning that its Phase 2 study of ezutromid failed to meet its primary or secondary endpoints.
from RTT - Before the Bell https://ift.tt/2KszhIp
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment